Skip to content
Draft
Show file tree
Hide file tree
Changes from all commits
Commits
File filter

Filter by extension

Filter by extension

Conversations
Failed to load comments.
Loading
Jump to
Jump to file
Failed to load files.
Loading
Diff view
Diff view
2 changes: 1 addition & 1 deletion plugins/life-science-research/.codex-plugin/plugin.json
Original file line number Diff line number Diff line change
@@ -1,6 +1,6 @@
{
"name": "life-science-research",
"version": "1.0.3",
"version": "1.1.0",
"description": "General life-sciences research workflows with query routing, evidence synthesis, and optional parallel subagent analysis across genetics, omics, biology, chemistry, structure, clinical evidence, and public dataset discovery.",
"author": {
"name": "OpenAI"
Expand Down
4 changes: 3 additions & 1 deletion plugins/life-science-research/README.md
Original file line number Diff line number Diff line change
Expand Up @@ -45,7 +45,7 @@ This plugin is meant to support workflows like:

## Skill Families

The plugin currently bundles 50 skills. The most useful way to think about them is by research area rather than as a flat list.
The plugin currently bundles 51 skills. The most useful way to think about them is by research area rather than as a flat list.

### Human Genetics And Variant Evidence

Expand Down Expand Up @@ -94,6 +94,7 @@ The plugin currently bundles 50 skills. The most useful way to think about them

### Clinical, Translational, And Disease Evidence

- `research-target-evidence-skill`
- `clinicaltrials-skill`
- `cbioportal-skill`
- `civic-skill`
Expand Down Expand Up @@ -165,6 +166,7 @@ Each subagent should receive a bounded objective and return concise findings, ca
- `Map the most plausible causal genes at this inflammatory bowel disease locus and explain why.`
- `Summarize known structure, ligand, and pathway information for EGFR.`
- `Pull ClinicalTrials.gov, ChEMBL, and PharmGKB context for JAK inhibitors in alopecia areata.`
- `Use $research-target-evidence-skill to separate human and preclinical evidence for ROR1 biology, therapeutic programs, and safety.`
- `Find metabolomics and proteomics resources relevant to MASLD and PPARG.`
- `Interpret this variant using ClinVar, gnomAD, Ensembl, and cohort association evidence.`

Expand Down
Original file line number Diff line number Diff line change
Expand Up @@ -68,6 +68,8 @@ Choose the smallest set of skills that can answer the question well.

Examples:

- bounded target biology, program, and safety review:
`research-target-evidence-skill`
- target or disease evidence review:
`opentargets-skill`, `gwas-catalog-skill`, `gtex-eqtl-skill`, `human-protein-atlas-skill`
- variant interpretation:
Expand All @@ -79,7 +81,7 @@ Examples:
- chemistry and pharmacology:
`chembl-skill`, `bindingdb-skill`, `pubchem-pug-skill`, `pharmgkb-skill`
- clinical and translational:
`clinicaltrials-skill`, `cbioportal-skill`, `civic-skill`
`research-target-evidence-skill`, `clinicaltrials-skill`, `cbioportal-skill`, `civic-skill`
- literature and dataset discovery:
`ncbi-entrez-skill`, `ncbi-pmc-skill`, `biorxiv-skill`, `biostudies-arrayexpress-skill`, `ncbi-datasets-skill`

Expand Down
Original file line number Diff line number Diff line change
@@ -0,0 +1,62 @@
---
name: research-target-evidence-skill
description: Produce bounded, source-backed evidence briefs for one or more biological targets, covering biology, therapeutic programs, human safety, preclinical evidence, and cross-target comparison. Use when a user asks for a target assessment, target comparison, translational evidence, program history, modality comparison, or human-versus-preclinical safety review and wants a fast primary-source research pass.
---

## Research Target Evidence

Use the bundled script exactly once for all requested targets. Let it plan,
deduplicate, globally pace, and batch requests across PubMed and
ClinicalTrials.gov.

Do not decompose the request into additional source calls unless the script
returns `ok=false` or the user explicitly asks for a deeper follow-up.

## Execution

For one target, run:

```bash
python scripts/research_target_evidence.py \
--target "<target>" \
--questions biology programs safety \
--separate-human-preclinical
```

For a comparison, repeat `--target` in the same command:

```bash
python scripts/research_target_evidence.py \
--target "<target 1>" \
--target "<target 2>" \
--target "<target 3>" \
--mode compare \
--questions biology programs safety \
--separate-human-preclinical
```

Do not run one process per target. The shared process enforces global source
pacing, preserves landmark-program and evidence-class quotas, and emits a
single size-bounded JSON result.

## Synthesis

- Lead with the target-level conclusion and the largest uncertainty.
- Separate human evidence from preclinical evidence.
- For comparisons, use the same evidence axes for every target and finish with
a compact comparison of validation, selectivity, safety, modality maturity,
and uncertainty.
- Cover only modalities supported by the returned papers or trial records.
- Link each PMID as `[PMID <id>](https://pubmed.ncbi.nlm.nih.gov/<id>/)`.
- Link each trial as `[<NCT id>](https://clinicaltrials.gov/study/<NCT id>)`.
- Distinguish observed human toxicity from preclinical or theoretical risk.
- Treat registry adverse-event counts as non-attributed unless the record says
otherwise.
- Preserve the returned limitations and current registry statuses.
- Report per-target errors or omitted evidence counts rather than silently
treating a partial result as complete.
- Keep the answer concise enough that the evidence hierarchy remains visible.

The retrieval is bounded and relevance-ranked, not a systematic review. Check
the script's heuristic human/preclinical classification during synthesis. Do
not include retrieval telemetry in the user-facing brief unless requested.
Original file line number Diff line number Diff line change
@@ -0,0 +1,4 @@
interface:
display_name: "Research Target Evidence"
short_description: "Bounded target evidence and comparison"
default_prompt: "Use $research-target-evidence-skill to assess or compare target biology, therapeutic programs, and safety evidence."
Loading